Skip to main content
  • University of California San Francisco
  • UCSF Health
  • Search UCSF
  • About UCSF
  • Give to UCSF
Pediatric Myasthenia Gravis Consortium
  • Home
  • Consortium Members
  • FAQs
  • MG Research
    • MG Adult Patient Registry (18+)
  • MG Resources
  1. Home
  2. MG Research
What We're Talking About
Top clinical studies and trials for Myasthenia Gravis

Alexion: Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Brief Summary:

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).

Learn more

Alexion: An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis. 

Brief Summary:

The primary objective of this study is to evaluate the efficacy of eculizumab in the treatment of pediatric refractory generalized myasthenia gravis (gMG) based on change from Baseline in the Quantitative Myasthenia Gravis score for disease severity (QMG). 

Learn more

Argenx: Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Brief Summary:

The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG.

Trial details include:

  • The maximum trial duration for each individual participant will be approximately 28 weeks
  • The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)

Learn more

 

Argenx: An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)

Brief Summary:

This is a randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.

Learn more

Hoffmann-La Roche: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Brief Summary:

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).

Learn more

Janssen: A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Brief Summary:

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).

Learn more

 

Quick Links

email us 

FAQS

Request an appointment

  • Contact Us
  • Accessibility
  • Privacy Policy
  • Terms of Use
  • A-Z Website List

© 2026 The Regents of the University of California